IN-SILICO APPROACH FOR PREDICTION OF VACCINE POTENTIAL ANTIGENIC PEPTIDES FROM 23-kDa TRANSMEMBRANE ANTIGEN PROTEIN OF Schistosoma haematobium
Authors: GOMASE V.S., CHITLANGE N.R., CHANGBHALE S.S., SHERKHANE A.S., KALE K.V
Number of views: 394
Urogenital schistosomiasis is frequently occurring parasitic disease in tropical countries, S. haematobium is main causative agent responcible for urogenital schistosomiasis; till date no effective invention made to against urogenital schistosomiasis. In this analysis we a have predicted suitable antigenic peptides from Schistosoma haematobium 23-kDa transmembrane protein for peptide vaccine design against urogenital schistosomiasis based on cross protection phenomenon as, an ample immune response can be generated with a single protein subunit. We found MHC class II binding peptides of S. haematobium 23-kDa are important determinant against the diseased condition. The analysis shows S. haematobium 23-kDa transmembrane protein having 218 amino acids, which shows 210 nonamers. In this assay, we have predicted MHC-I binding peptides for 8mer_H2_Db allele (optimal score is 14.128), 9mer_H2_Db allele (optimal score is 20.065), 10mer_H2_Db allele (optimal score is 13.776), 11mer_H2_Db allele (optimal score is 31.213). We also predicted the SVM based MHCII-IAb peptide regions, 152-DYGPNIPAS, 51-WQAAPIAII, 50-VWQAAPIAI, 142-FHCCGAKGP, 97-AELAAAIVA (optimal score is 14.911); MHCII-IAd peptide regions, 100-AAAIVAVVY, 71-LGCCGAIKE, 192-FGVCFFQLL, 186-IVACVAFGV (optimal score is 13.112); and MHCII-IAg7 peptide regions 42-QYGDNLHKV, 101-AAIVAVVYK, 28-VLIGAGAYV, 103-IVAVVYKDR, 203-VIACCLGRQ (optimal score is 11.605) which shows potential binders from S. haematobium 23-kDa transmembrane protein. The method integrates prediction of MHC class I binding proteasomal C- terminal cleavage peptides and Six potential antigenic peptides at average propensity 1.094 having highest local hydrophilicity. Thus a small antigen fragment can induce immune response against whole antigen. This approach can be applied for designing subunit and synthetic peptide vaccines.